Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Recurrence 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

pembrolizumab 5Nivolumab 4Cisplatin 4Paclitaxel 3Ifosfamide 3avelumab 2aldesleukin 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Ipilimumab 2vinflunine 1toripalimab 1rocakinogene sifuplasmid 1niraparib 1nimotuzumab 1lenvatinib 1fludarabine phosphate 1fludarabine 1enfortumab vedotin 1durvalumab 1dostarlimab 1dacomitinib 1cemiplimab 1cabozantinib 1cabazitaxel 1Vorinostat 1VGX-3100 1Specimen Handling 1Ritonavir 1Neoadjuvant Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Penile Neoplasms × MEDI0457 × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡